Teneliximab
From Wikipedia, the free encyclopedia
Monoclonal antibody
Pharmaceutical compound
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | CD40 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
 N Y (what is this?) (verify) | |
Teneliximab is a chimeric monoclonal antibody[1] binding to the immune stimulatory protein CD40.[2] As of 2009[update], it has not entered clinical trials.[2]
- ↑ International Nonproprietary Names For Pharmaceutical Substances
- 1 2 Law CL, Grewal IS (2009). "Therapeutic Interventions Targeting CD40L (CD154) and CD40: The Opportunities and Challenges". Therapeutic Targets of the TNF Superfamily. Advances in Experimental Medicine and Biology. Vol. 647. New York, N.Y.: Springer Science+Business Media. pp. 8–36. doi:10.1007/978-0-387-89520-8_2. ISBN 978-0-387-89520-8. PMID 19760064.
| Intracellular (initiation) |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular (reception) |
| ||||||||||||||
| Extracellular |
| ||||||||||||||
| Unsorted |
| ||||||||||||||
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |